Pipeline Highlights: AAT Ph2/3 Trial Design, AAT and HBV EASL Presentations, Dosing Starts in ARO-ANG3/APOC3 Ph 1s Arrowhead Pharmaceuticals (ARWR) continues to make rapid progress across most of ...
Kamada Ltd. KMDA announced that the FDA has acknowledged the path forward for commencing a phase III study on the inhaled Alpha-1 Antitrypsin (Inhaled AAT) product, which is being developed for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback